User: Guest  Login
Title:

Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.

Document type:
Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Article
Author(s):
Lopes, RD; Alexander, JH; Al-Khatib, SM; Ansell, J; Diaz, R; Easton, JD; Gersh, BJ; Granger, CB; Hanna, M; Horowitz, J; Hylek, EM; McMurray, JJ; Verheugt, FW; Wallentin, L
Abstract:
Atrial fibrillation (AF) is associated with increased risk of stroke that can be attenuated with vitamin K antagonists (VKAs). Vitamin K antagonist use is limited, in part, by the high incidence of complications when patients' international normalized ratios (INRs) deviate from the target range. The primary objective of ARISTOTLE is to determine if the factor Xa inhibitor, apixaban, is noninferior to warfarin at reducing the combined endpoint of stroke (ischemic or hemorrhagic) and systemic embo...     »
Journal title abbreviation:
Am Heart J
Year:
2010
Journal volume:
159
Journal issue:
3
Pages contribution:
331-9
Language:
eng
Fulltext / DOI:
doi:10.1016/j.ahj.2009.07.035
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/20211292
Print-ISSN:
0002-8703
TUM Institution:
Neurologische Klinik und Poliklinik
 BibTeX